At a pivotal moment, Biogen loses another top executive
While Biogen’s top products are facing tough competition and the biotech is trying to secure approval for what could be a first-of-its-kind Alzheimer’s disease drug, the company is faced with an executive change-up.
Chief Financial Officer Jeff Capello will be replaced with Mike McDonnell, who holds the same position at Iqvia. Capello is the second executive to depart in less than a year, following Michael Ehlers, the former Head of R&D who left in mid-October.
